Evidence map›Paper›PMID 38794124›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Effects of

Daniel N Marco, Mònica Molina, Ana-María Guio, Judit Julian, Virginia Fortuna, Virginia-Lucila Fabregat-Zaragoza, María-Queralt Salas, Inés Monge-Escartín, Gisela Riu-Viladoms, Esther Carcelero and 9 more

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Daniel N MarcoHematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Instituto de Investigación Biomédica August Pi i Sunyer (IDIBAPS), Hospital Clínic, 08036 Barcelona, Spain.ORCID 0000-0003-3412-7563
Mònica MolinaHematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Instituto de Investigación Biomédica August Pi i Sunyer (IDIBAPS), Hospital Clínic, 08036 Barcelona, Spain.
Ana-María GuioHematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Instituto de Investigación Biomédica August Pi i Sunyer (IDIBAPS), Hospital Clínic, 08036 Barcelona, Spain.
Judit JulianPharmacology and Toxicology Laboratory, Biochemistry and Molecular Genetics Department, Biomedical Diagnostic Center, IDIBAPS, CIBERehd, Hospital Clínic, 08036 Barcelona, Spain.ORCID 0009-0008-7137-9210
Virginia FortunaPharmacology and Toxicology Laboratory, Biochemistry and Molecular Genetics Department, Biomedical Diagnostic Center, IDIBAPS, CIBERehd, Hospital Clínic, 08036 Barcelona, Spain.
Virginia-Lucila Fabregat-ZaragozaDepartment of Immunology, Hospital Clínic, 08036 Barcelona, Spain.
María-Queralt SalasHematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Instituto de Investigación Biomédica August Pi i Sunyer (IDIBAPS), Hospital Clínic, 08036 Barcelona, Spain.ORCID 0000-0003-4567-3682
Inés Monge-EscartínDepartment of Pharmacy, Pharmacy Service, Hospital Clínic, 08036 Barcelona, Spain.ORCID 0000-0001-9959-9102
Gisela Riu-ViladomsDepartment of Pharmacy, Pharmacy Service, Hospital Clínic, 08036 Barcelona, Spain.ORCID 0000-0002-8259-0811
Esther CarceleroDepartment of Pharmacy, Pharmacy Service, Hospital Clínic, 08036 Barcelona, Spain.
Joan Ramón RomaDepartment of Pharmacy, Pharmacy Service, Hospital Clínic, 08036 Barcelona, Spain.
Noemí LlobetHematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Instituto de Investigación Biomédica August Pi i Sunyer (IDIBAPS), Hospital Clínic, 08036 Barcelona, Spain.
Jordi ArcaronsHematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Instituto de Investigación Biomédica August Pi i Sunyer (IDIBAPS), Hospital Clínic, 08036 Barcelona, Spain.
María Suárez-LledóHematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Instituto de Investigación Biomédica August Pi i Sunyer (IDIBAPS), Hospital Clínic, 08036 Barcelona, Spain.
Laura RosiñolHematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Instituto de Investigación Biomédica August Pi i Sunyer (IDIBAPS), Hospital Clínic, 08036 Barcelona, Spain.ORCID 0000-0002-2534-9239
Francesc Fernández-AvilésHematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Instituto de Investigación Biomédica August Pi i Sunyer (IDIBAPS), Hospital Clínic, 08036 Barcelona, Spain.ORCID 0000-0002-3733-590X
Montserrat RoviraHematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Instituto de Investigación Biomédica August Pi i Sunyer (IDIBAPS), Hospital Clínic, 08036 Barcelona, Spain.
Mercè BrunetPharmacology and Toxicology Laboratory, Biochemistry and Molecular Genetics Department, Biomedical Diagnostic Center, IDIBAPS, CIBERehd, Hospital Clínic, 08036 Barcelona, Spain.
Carmen MartínezHematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Instituto de Investigación Biomédica August Pi i Sunyer (IDIBAPS), Hospital Clínic, 08036 Barcelona, Spain.ORCID 0000-0002-8401-7306

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tacrolimus (Tac) is pivotal in preventing acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (alloHSCT). It has been reported that genetic factors, including

Indexed as

allogeneic hematopoietic stem cell transplantationCYP3A5 genotypegraft-versus-host diseasepreemptive pharmacogeneticstacrolimustherapeutic drug monitoring

Identifiers

PMID38794124
PMCPMC11124388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.